The ISSCR and Harvard Medical School have launched an online course, Stem Cell Medicine: From Scientific Research to Patient Care, aiming to educate healthcare professionals on stem cell biology and clinical applications.
The course addresses the risks posed by unverified stem cell therapies and emphasizes scientific integrity and patient safety amidst the proliferation of unregulated treatments.
Chaired by Dr. Eugenia Piddini, the ISSCR Education Committee developed the course to prepare clinicians for the evolving landscape of validated stem cell-based therapies.
With a focus on patient care, the course integrates basic stem cell biology, therapeutic mechanisms, and patient engagement strategies to bridge the knowledge gap for clinicians.
Participants learn about different stem cell types, their therapeutic potentials, clinical trial methodologies, and ethical considerations in stem cell medicine.
The course provides insights into ongoing clinical trials targeting various conditions and emphasizes the importance of discerning valid claims in stem cell interventions.
It also educates on regulatory oversight, approval criteria for regenerative therapies, and the distinction between experimental and approved treatments.
Offered in six languages at no cost, the course promotes accessibility to high-quality stem cell education globally and provides continuing medical education credits.
Industry leaders like Novo Nordisk and Bayer AG generously funded this educational effort to support informed clinical communities in responsibly integrating stem cell technologies.
By empowering healthcare providers with scientific knowledge and ethical awareness, the ISSCR course aims to fortify patient care against misinformation and foster a vigilant healthcare environment.